title: Non-metastatic upper tract transitional cell carcinoma: single center experience.
abstract: BACKGROUND
  Upper tract transitional cell carcinomas (UTCC) are relatively uncommon but prognosis is generally worse than TCC of bladder.
  
  
  METHODS
  Between March 2004 and June 2012, patients with initial non- metastatic UTCC were assessed in the Medical Oncology and Urology Departments of Ataturk Training and Research Hospital.
  
  
  RESULTS
  A total of 11 patients with initially non-metastatic UTCC were detected in the 8 year period, all males. Median age of was 62 (range, 38-74). Six lesions were located in the renal pelvis and 5 in the ureter. Nephroureterectomy was performed in 9 patients, and distal ureterectomy and cuff excision of the bladder in the remaining 2. The majority (n= 9) had high grade tumors. Median primary tumor diameter was 3.5 cm (range, 0.7-10). Five patients (45.5%) were stage I, 2 (18.2%) were stage II, and 4 (36.4%) were stage III. While adjuvant chemotherapy was not applied for stage I and II disease (n= 7), 4 to 6 courses were applied for 3 of the stage III patients. Also one stage III case received adjuvant radiotherapy. Up to 100 months follow-up, median overall survival was 13 months (range, 5-100 months). While stage I and II patients are following-up without muscle-invasive progression, 2 of stage III patients demonstrated progression.
  
  
  CONCLUSIONS
  We need more collaborative studies to determine management of especially pT3-pT4 patients with UTCC.
authors.affiliation: Department of Medical Oncology, Ataturk Training and Research Hospital, Ankara, Turkey. drumutdemirci@gmail.com
authors.forename: Umut
authors.initials: U
authors.lastname: Demirci
authors.forename: Abdullah Erdem
authors.initials: AE
authors.lastname: Canda
authors.forename: Didem Sener
authors.initials: DS
authors.lastname: Dede
authors.forename: Ozer Ural
authors.initials: OU
authors.lastname: Cakici
authors.forename: Muhammed Bulent
authors.initials: MB
authors.lastname: Akinci
authors.forename: Bulent
authors.initials: B
authors.lastname: Yalcin
mesh_terms: D000328:Adult; D000368:Aged; D002295:Carcinoma, Transitional Cell / Q000401:mortality* / Q000532:radiotherapy / Q000601:surgery; D006801:Humans; D007680:Kidney Neoplasms / Q000401:mortality* / Q000532:radiotherapy / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009399:Nephrons / Q000601:surgery; D018714:Radiotherapy, Adjuvant; D013534:Survival; D016896:Treatment Outcome; D014513:Ureter / Q000473:pathology / Q000601:surgery; D014516:Ureteral Neoplasms / Q000401:mortality* / Q000532:radiotherapy / Q000601:surgery; D001743:Urinary Bladder / Q000473:pathology / Q000601:surgery; D001749:Urinary Bladder Neoplasms / Q000401:mortality* / Q000532:radiotherapy / Q000601:surgery